- Home
- GPRK vs FLGT Comparison
GPRK vs FLGT Comparison
Compare GPRK & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GPRK | FLGT |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | Colombia | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 586.7M | 511.2M |
| IPO Year | 2009 | 2016 |
Fundamental Metrics
Financial Performance| Metric | GPRK | FLGT |
|---|---|---|
| Price | $10.28 | $20.28 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $8.50 | ★ $28.33 |
| AVG Volume (30 Days) | ★ 469.4K | 266.1K |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.26% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,730,000.00 |
| Revenue This Year | $39.45 | $10.09 |
| Revenue Next Year | N/A | $12.18 |
| P/E Ratio | $12.70 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.75 | $13.46 |
| 52 Week High | $11.87 | $31.04 |
Technical Indicators
Market Signals| Indicator | GPRK | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 58.10 | 60.34 |
| Support Level | $7.87 | $13.91 |
| Resistance Level | $11.77 | $21.59 |
| Average True Range (ATR) | 0.31 | 0.68 |
| MACD | 0.10 | -0.05 |
| Stochastic Oscillator | 99.30 | 66.03 |
Price Performance
Historical ComparisonAbout GPRK Geopark Ltd
GeoPark Ltd is an independent energy company. Its diversified portfolio of assets consist of Llanos 34 Block in Colombia, CPO-5 Block, Llanos 86, Llanos 87, Llanos 104, Llanos 123, and Llanos 124 Blocks in the Llanos Basin. Its segments include Colombia, Argentina, Brazil and Ecuador, with the majority of the revenue derived from Colombia. It derives revenue from Sale of crude oil, Sale of purchased crude oil, and Sale of gas.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.